Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
M6223 targets and binds to TIGIT on immune cells, including tumor-infiltrating lymphocytes, and prevents its interaction with CD112 and CD155, thereby leading to enhanced interaction of CD112 and CD155 with CD226 expressed on natural killer and CD8 T+ cells, which may lead to the activation of anti-tumor immune responses (NCI Drug Dictionary).
|CAS Registry Number||NA|
|Therapy Name||Drugs||Efficacy Evidence||Clinical Trials|
|Avelumab + M6223||Avelumab M6223||0||1|
|M6223 + M7824||M6223 M7824||0||1|